SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
Chemical Name: 4-amino-5-(3,4,5-trimethoxybenzyl)pyrimidin-2-ol
Synonym: Trimethoprim USP Related Compound A
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
Smiles: OC1=NC=C(CC2=CC(OC)=C(OC)C(OC)=C2)C(N)=N1
Trimethoprim EP Impurity E is chemically 4-amino-5-(3,4,5-trimethoxybenzyl)pyrimidin-2-ol. It is also known as Trimethoprim USP Related Compound A . Trimethoprim EP Impurity E is supplied with detailed characterization data compliant with regulatory guideline. Trimethoprim EP Impurity E can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Trimethoprim.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Comparison between liquid chromatography–UV detection and liquid chromatography–mass spectrometry for the characterization of impurities and/or degradants present in trimethoprim tablets
Nicolas Barbarin, Jack D Henion, Yunhui Wu
Journal of Chromatography A Volume 970, Issues 1–2, 13 September 2002, Pages 141-154
Trace Analysis of Trimethoprim and Sulfonamide, Macrolide, Quinolone, and Tetracycline Antibiotics in Chlorinated Drinking Water Using Liquid Chromatography Electrospray Tandem Mass Spectrometry
Zhengqi Ye, Howard S. Weinberg, and Michael T. Meyer
Anal. Chem. 2007, 79, 3, 1135–1144
Preparation and Characterization of Amino Acids-Based Trimethoprim Salts
Amr ElShaer,Peter Hanson,Tony Worthington,Peter Lambert and Afzal R. Mohammed
Pharmaceutics 2012, 4(1), 179-196